Monthly Archives: November 2016

http://www.lslog.com/valeant-and-takedas-10b-salix-deal-talks-scuttled-by-price-squabbles-wsj/Valeant and Takeda's $10B Salix deal talks scuttled by price squabbles: WSJ

Valeant and Takeda's $10B Salix deal talks scuttled by price squabbles: WSJ

Valeant and Takeda’s B Salix deal talks scuttled by price squabbles: WSJ Valeant and Takeda’s $10B Salix deal talks scuttled by price squabbles: WSJ chelfand Wed, 11/30/2016 – 11:46 […]

http://www.lslog.com/pfizers-herceptin-biosim-posts-encouraging-phase-3-data-in-blockbuster-sales-battle/Pfizer's Herceptin biosim posts 'encouraging' phase 3 data in blockbuster sales battle

Pfizer's Herceptin biosim posts 'encouraging' phase 3 data in blockbuster sales battle

Pfizer’s Herceptin biosim posts ‘encouraging’ phase 3 data in blockbuster sales battle Pfizer’s Herceptin biosim posts ‘encouraging’ phase 3 data in blockbuster sales battle esagonowsky Wed, 11/30/2016 – 11:21 […]

http://www.lslog.com/early-data-on-oncomeds-cancer-antibodies-intriguing-but-preliminary/Early data on OncoMed's cancer antibodies 'intriguing, but preliminary'

Early data on OncoMed's cancer antibodies 'intriguing, but preliminary'

Early data on OncoMed’s cancer antibodies ‘intriguing, but preliminary’ Early data on OncoMed’s cancer antibodies ‘intriguing, but preliminary’ phil Wed, 11/30/2016 – 08:08 Source: FierceMedicalDevices News Early data on […]

http://www.lslog.com/takeover-hungry-jj-hikes-its-actelion-bid-past-26b/Takeover-hungry J&J hikes its Actelion bid past $26B

Takeover-hungry J&J hikes its Actelion bid past $26B

Takeover-hungry J&J hikes its Actelion bid past B Takeover-hungry J&J hikes its Actelion bid past $26B chelfand Tue, 11/29/2016 – 17:22 Source: Fierce Pharma Takeover-hungry J&J hikes its Actelion […]

http://www.lslog.com/weakened-pound-piles-the-pain-on-price-pressured-novo-nordisk/Weakened pound piles the pain on price-pressured Novo Nordisk

Weakened pound piles the pain on price-pressured Novo Nordisk

Weakened pound piles the pain on price-pressured Novo Nordisk Weakened pound piles the pain on price-pressured Novo Nordisk chelfand Tue, 11/29/2016 – 11:37 Source: Fierce Pharma Weakened pound piles […]

http://www.lslog.com/pfizer-partner-german-merck-see-fda-accept-pd-l1-candidate-for-speedy-review/Pfizer, partner German Merck see FDA accept PD-L1 candidate for speedy review

Pfizer, partner German Merck see FDA accept PD-L1 candidate for speedy review

Pfizer, partner German Merck see FDA accept PD-L1 candidate for speedy review Pfizer, partner German Merck see FDA accept PD-L1 candidate for speedy review badams Tue, 11/29/2016 – 09:50 […]

http://www.lslog.com/boehringer-strikes-second-blue-sky-research-project-aimed-at-defeating-deafness/Boehringer strikes second blue-sky research project aimed at defeating deafness

Boehringer strikes second blue-sky research project aimed at defeating deafness

Boehringer strikes second blue-sky research project aimed at defeating deafness Boehringer strikes second blue-sky research project aimed at defeating deafness phil Tue, 11/29/2016 – 08:42 Source: FierceMedicalDevices News Boehringer […]

http://www.lslog.com/nih-others-launch-historic-hiv-trial-with-vaccines-from-gsk-sanofi/NIH, others launch 'historic' HIV trial with vaccines from GSK, Sanofi

NIH, others launch 'historic' HIV trial with vaccines from GSK, Sanofi

NIH, others launch ‘historic’ HIV trial with vaccines from GSK, Sanofi NIH, others launch ‘historic’ HIV trial with vaccines from GSK, Sanofi esagonowsky Mon, 11/28/2016 – 14:30 Source: Fierce […]

http://www.lslog.com/formatting-failings-set-to-delay-fda-ruling-on-cancer-drug/Formatting failings set to delay FDA ruling on cancer drug

Formatting failings set to delay FDA ruling on cancer drug

Formatting failings set to delay FDA ruling on cancer drug Formatting failings set to delay FDA ruling on cancer drug nick.paul.taylor Mon, 11/28/2016 – 12:12 Source: FierceMedicalDevices News Formatting […]

http://www.lslog.com/mercks-keytruda-nabs-fdas-priority-tag-in-microsatellite-instability-high-cancer/Merck's Keytruda nabs FDA's 'priority' tag in microsatellite instability-high cancer

Merck's Keytruda nabs FDA's 'priority' tag in microsatellite instability-high cancer

Merck’s Keytruda nabs FDA’s ‘priority’ tag in microsatellite instability-high cancer Merck’s Keytruda nabs FDA’s ‘priority’ tag in microsatellite instability-high cancer chelfand Mon, 11/28/2016 – 11:50 Source: Fierce Pharma Merck’s […]